As a direct consequence of the enhanced integration (objective 1), it will become more feasible to better streamline the translational pipeline from in vitro target identification to in vivo biomarker validation.
Collaborations with pharmaceutical companies for drug screening, direct access to clinic-ready PET ligands, a dedicated research human PET and MR scanner, and expertise in conducting multi-center clinical trials are strong assets for extending running fundamental research lines from bench to bedside.
The closer collaboration and direct communication between preclinical and clinical research teams in the our consortium will improve the translational return. Identification of novel clinical cases or therapeutic compounds will benefit from enhanced insight in the molecular and cellular mechanisms. Herein, the use of novel, more sensitive and/or comprehensive interrogation paradigms will be crucial.